{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:31:24Z","timestamp":1793140284469,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018712","name":"Universitatea de Medicin\u0103 \u015fi Farmacie Iuliu Ha\u0163ieganu Cluj-Napoca","doi-asserted-by":"publisher","award":["project no. 100418\/29.08.2025, SMIS code 350525"],"award-info":[{"award-number":["project no. 100418\/29.08.2025, SMIS code 350525"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    Hepatocellular carcinoma (HCC) is undergoing a profound global epidemiological shift, transitioning from viral-driven etiologies to metabolic dysfunction-associated steatotic liver disease (MASLD). This transition challenges traditional cirrhosis-centric surveillance, as a significant proportion of MASLD-HCC develops in non-cirrhotic livers. Parallel to these metabolic shifts, the gut-liver axis has emerged as a central orchestrator of hepatocarcinogenesis. This review decodes the complex gut-driven pathways fueling HCC, highlighting the oncogenic consequences of structural and functional dysbiosis. Dietary patterns and etiology-specific microbial shifts compromise the intestinal and gut-vascular barriers, precipitating a structural \u201cleaky gut\u201d. This disruption facilitates the robust translocation of pathogen-associated molecular patterns (PAMPs), particularly lipopolysaccharide (LPS), and toxic microbial metabolites like secondary bile acids, specifically deoxycholic acid, into the portal circulation. Consequently, hepatic innate immunity is chronically activated via Toll-like receptor 4 (TLR4) signaling on Kupffer and hepatic stellate cells, fostering metainflammation, cellular senescence, genomic instability, and a highly immunosuppressive, pro-tumorigenic microenvironment. Furthermore, the depletion of keystone commensals diminishes the protective reservoir of short-chain fatty acids (SCFAs), exacerbating oncogene activation. Translating these mechanistic insights into the clinic, we explore the utility of distinct microbial signatures and metabolomic profiles as non-invasive diagnostic biomarkers. Such tools are urgently needed to bridge the early-detection gap in the expanding MASLD demographic. Finally, we discuss the pivotal role of the microbiome in modulating responses to immune checkpoint inhibitors (ICIs), notably through immune-stimulating taxa like\n                    <jats:italic>Akkermansia muciniphila<\/jats:italic>\n                    , and outline emerging gut-targeted therapies, including next-generation probiotics and fecal microbiota transplantation, aimed at restoring host-microbiome homeostasis to prevent and manage HCC. By decoding these gut-driven pathways, this review provides a comprehensive framework for integrating the microbiome-onco axis into precision oncology, offering novel avenues to combat the rising global burden of hepatocellular carcinoma.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2026.1852380","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:42:49Z","timestamp":1780983769000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Abdulrahman","family":"Ismaiel","sequence":"first","affiliation":[{"name":"2nd Department of Internal Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhd Bashir","family":"Almonajjed","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Wardeh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelghafar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan-Lucian","family":"Popa","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sabo","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan L.","family":"Dumitrascu","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy","place":["Cluj-Napoca, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2902067","article-title":"Gut microbiome and cancer: From cancer development to therapeutics with a special focus on hepatocellular carcinoma","volume":"29","author":"Acharya","year":"2024","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118562","article-title":"Pathophysiological mechanisms underlying diarrhea across generations of EGFR-TKIs: The role of ERBB signaling and potential therapies","volume":"184","author":"Ariyadamrongkwan","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14202278","article-title":"Novel biomarkers for early detection of hepatocellular carcinoma","volume":"14","author":"Attia","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12091946","article-title":"Circulating gut microbe-derived metabolites are associated with hepatocellular carcinoma","volume":"12","author":"Banerjee","year":"2024","journal-title":"Biomedicines"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32100577","article-title":"Akkermansia muciniphila and HCC: A gut feeling","volume":"32","author":"Capasso","year":"2025","journal-title":"Curr. Oncol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568962","article-title":"Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1179014","article-title":"Lactobacillus brevis alleviates the progress of hepatocellular carcinoma and type 2 diabetes in mice model via interplay of gut microflora, bile acid and NOTCH 1 signaling","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70458","article-title":"The gut\u2013liver axis in liver disease: Molecular mechanisms and therapeutic targets","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1159\/000518090","article-title":"Use of antibiotics during immune checkpoint inhibitor treatment is associated with lower survival in hepatocellular carcinoma","volume":"10","author":"Cheung","year":"2021","journal-title":"Liver Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2024.1434799","article-title":"Advanced computational tools, artificial intelligence and machine-learning approaches in gut microbiota and biomarker identification","volume":"6","author":"Dakal","year":"2025","journal-title":"Front. Med. Technol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/HEP.0000000000000406","article-title":"The role of the gut microbiome in the development of hepatobiliary cancers","volume":"80","author":"Daniel","year":"2024","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1575963","article-title":"The multifaceted role of microbiota in liver cancer: Pathogenesis, therapy, prognosis, and immunotherapy","volume":"16","author":"Feng","year":"2025","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/genes16080920","article-title":"Genomic alterations and microbiota crosstalk in hepatic cancers: The gut\u2013liver axis in tumorigenesis and therapy","volume":"16","author":"Fu","year":"2025","journal-title":"Genes (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/gutjnl-2023-331740","article-title":"Artificial intelligence applied to 'omics data in liver disease: Towards a personalised approach for diagnosis, prognosis and treatment","volume":"74","author":"Ghosh","year":"2025","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12935-025-03840-9","article-title":"Understanding crosstalk between the gut and liver microbiome: Pathogenesis to therapeutic approaches in liver cancer","volume":"25","author":"Goyal","year":"2025","journal-title":"Cancer Cell Int."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044089","article-title":"The gut-organ-axis concept: Advances the application of gut-on-chip technology","volume":"24","author":"Guo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10238-025-01906-6","article-title":"Mechanistic roles and intervention strategies involving gut microbiota, amino acid metabolism, and the tumor immune microenvironment in MAFLD-HCC progression","volume":"26","author":"Guo","year":"2026","journal-title":"Clin. Exp. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13099-025-00761-w","article-title":"Gut microbiome dysbiosis in hepatocellular carcinoma patients with persistent HCV viremia versus viral clearance: A cross-sectional study","volume":"17","author":"Hashem","year":"2025","journal-title":"Gut Pathog."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1039\/D4BM01273A","article-title":"Microfluidic organ-on-a-chip models for the gut-liver axis: From structural mimicry to functional insights","volume":"13","author":"Hu","year":"2025","journal-title":"Biomater. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3390\/curroncol30020141","article-title":"Altered gut microbiota composition and its potential association in patients with advanced hepatocellular carcinoma","volume":"30","author":"Huo","year":"2023","journal-title":"Curr. Oncol."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.00765-24","article-title":"Association of intratumoral microbiome diversity with hepatocellular carcinoma prognosis","volume":"9","author":"Jiang","year":"2024","journal-title":"mSystems"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.7150\/ijbs.117394","article-title":"Immunotherapy resistance in MASLD-related hepatocellular carcinoma: Special immune microenvironment and gut microbiota","volume":"21","author":"Jin","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00253-023-12845-1","article-title":"Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma","volume":"108","author":"Jinato","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"26092","DOI":"10.1038\/s41598-024-77260-6","article-title":"Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues","volume":"14","author":"Jo","year":"2024","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00194","article-title":"Translational implications of microbiome testing methodologies in lung cancer: A systematic review of 16S rRNA sequencing, shotgun metagenomics, and short-chain fatty acid profiling","volume":"3","author":"Kapoor","year":"2026","journal-title":"JCO Oncol. Adv."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.26355\/eurrev_202112_27421","article-title":"The potential of gut microbiome as a non-invasive predictive biomarker for early detection of pancreatic cancer and hepatocellular carcinoma","volume":"25","author":"Ka\u017amierczak-Siedlecka","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101414","article-title":"Inflammation in MASLD progression and cancer","volume":"7","author":"Kim","year":"2025","journal-title":"JHEP Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1038\/s41598-021-89963-1","article-title":"Profiling of tumour-associated microbiota in human hepatocellular carcinoma","volume":"11","author":"Komiyama","year":"2021","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2412.12075","article-title":"The gut microbiome in hepatocellular carcinoma: Proliferation, inhibition, diagnosis, and immunotherapy","volume":"35","author":"Lee","year":"2025","journal-title":"J. Microbiol. Biotechnol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3350\/cmh.2024.0857","article-title":"Gut microbiota-mediated gut-liver axis: A breakthrough point for understanding and treating liver cancer","volume":"31","author":"Li","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24512","article-title":"Research progress of gut microbiota in hepatocellular carcinoma","volume":"36","author":"Li","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1701101","article-title":"Analyzing the gut liver axis: A dual role of the microbiome in the genesis, progression, and treatment of liver cell carcinoma","volume":"16","author":"Li","year":"2025","journal-title":"Front. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1500863","article-title":"Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma","volume":"15","author":"Lin","year":"2025","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1333864","article-title":"Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1140126","article-title":"Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jcmgh.2023.01.004","article-title":"Gut microbiota-derived glutamine attenuates liver ischemia\/reperfusion injury via macrophage metabolic reprogramming","volume":"15","author":"Lu","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.873160","article-title":"Hepatocellular carcinoma: How the gut microbiota contributes to pathogenesis, diagnosis, and therapy","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Microbiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/ijo.2022.5407","article-title":"Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids","volume":"61","author":"Luo","year":"2022","journal-title":"Int. J. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"42932","DOI":"10.1038\/s41598-025-28663-6","article-title":"Diagnostic significance of gut microbiome dysbiosis and biomarker expression in Egyptians with hepatocellular carcinoma","volume":"15","author":"Marawan","year":"2025","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells14020084","article-title":"Gut microbiome modulation in hepatocellular carcinoma: Preventive role in NAFLD\/NASH progression and potential applications in immunotherapy-based strategies","volume":"14","author":"Monti","year":"2025","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.7150\/thno.125301","article-title":"Advances in the engineering of living probiotics for cancer immunotherapy","volume":"16","author":"Muhammad","year":"2026","journal-title":"Theranostics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146710","article-title":"Rifaximin attenuates liver fibrosis and hepatocarcinogenesis in a rat MASH model by suppressing the gut\u2013liver axis and epiregulin\u2013IL-8-associated angiogenesis","volume":"26","author":"Nishimura","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000241","article-title":"Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD\/NASH, HCC, and beyond","volume":"7","author":"Ohtani","year":"2023","journal-title":"Hepatol. Commun."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006817","article-title":"2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis","volume":"11","author":"Pan","year":"2023","journal-title":"J. ImmunoTher. Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19274","article-title":"Hepatocellular carcinoma in 2021: An exhaustive update","volume":"13","author":"Philips","year":"2021","journal-title":"Cureus"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321189","article-title":"Study protocol: Fecal microbiota transplant combined with atezolizumab\/bevacizumab in patients with hepatocellular carcinoma who failed to achieve or maintain objective response to atezolizumab\/bevacizumab \u2013 the FAB-HCC pilot study","volume":"20","author":"Pomej","year":"2025","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/hep4.1905","article-title":"Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"6","author":"Ponziani","year":"2022","journal-title":"Hepatol. Commun."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1326097","article-title":"Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"14","author":"Qin","year":"2023","journal-title":"Front. Immunol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2240031","article-title":"Unveiling the complex relationship between gut microbiota and liver cancer: Opportunities for novel therapeutic interventions","volume":"15","author":"Rajapakse","year":"2023","journal-title":"Gut Microbes"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/gutjnl-2017-315084","article-title":"Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma","volume":"68","author":"Ren","year":"2019","journal-title":"Gut"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1526967","article-title":"Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma","volume":"16","author":"Ren","year":"2025","journal-title":"Front. Immunol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081797","article-title":"Gut microbiota, deranged immunity, and hepatocellular carcinoma","volume":"12","author":"Scarpellini","year":"2024","journal-title":"Biomedicines"},{"key":"B54","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12072-022-10299-7","article-title":"Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma","volume":"16","author":"Shen","year":"2022","journal-title":"Hepatol. Int."},{"key":"B55","doi-asserted-by":"publisher","first-page":"917","DOI":"10.20892\/j.issn.2095-3941.2023.0394","article-title":"Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma","volume":"20","author":"Song","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41598-025-31225-5","article-title":"The gut microbiota as a potential biomarker in patients with EGFR-mutant lung cancer","volume":"16","author":"Tabe","year":"2026","journal-title":"Sci. Rep."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43862","article-title":"The role of gut microbiome in hepatocellular carcinoma: A systematic review","volume":"15","author":"Trivedi","year":"2023","journal-title":"Cureus"},{"key":"B59","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41564-024-01890-9","article-title":"Gut\u2013liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice","volume":"10","author":"Wang","year":"2025","journal-title":"Nat. Microbiol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2025.100073","article-title":"Pathological and therapeutic roles of bile acid metabolism and signaling in hepatocellular carcinoma: Insights from human and mouse studies","volume":"205","author":"Wang","year":"2025","journal-title":"Pharmacol. Res."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2026.1782471","article-title":"Characterization of dysbiosis patterns in gut microbiota of digestive system cancers: An umbrella review","volume":"17","author":"Wang","year":"2026","journal-title":"Front. Microbiol."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2024.13375","article-title":"Gut-liver axis in liver disease: From basic science to clinical treatment","volume":"31","author":"Wang","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.24976\/Discov.Med.202436189.181","article-title":"Gut-liver axis: Modulating the gut microbiota and its metabolic products as a potential therapeutic strategy for the treatment of hepatic ischemia-reperfusion injury","volume":"36","author":"Wang","year":"2024","journal-title":"Discov. Med."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1467197","article-title":"Microbiome interplays in the gut-liver axis: Implications for liver cancer pathogenesis and therapeutic insights","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111036","article-title":"The gut microbiome-bile acid axis in hepatocarcinogenesis","volume":"133","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101900","article-title":"Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma","volume":"6","author":"Wu","year":"2025","journal-title":"Cell Rep. Med."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70914","article-title":"Gut microbiota and hepatocellular carcinoma: Metabolic products and immunotherapy modulation","volume":"14","author":"Xiao","year":"2025","journal-title":"Cancer Med."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10070782","article-title":"Clinical aspects of gut microbiota in hepatocellular carcinoma management","volume":"10","author":"Xu","year":"2021","journal-title":"Pathogens"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2201159","article-title":"A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma","volume":"15","author":"Yang","year":"2023","journal-title":"Gut Microbes"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32120673","article-title":"Important role of bacterial metabolites in development and adjuvant therapy for hepatocellular carcinoma","volume":"32","author":"Ye","year":"2025","journal-title":"Curr. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"556","DOI":"10.37349\/etat.2023.00152","article-title":"Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma","volume":"4","author":"Yoshikawa","year":"2023","journal-title":"Explor. Target Antitumor Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.tem.2024.06.003","article-title":"Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment","volume":"35","author":"Yu","year":"2024","journal-title":"Trends Endocrinol. Metab"},{"key":"B73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2023.11.011","article-title":"Bifidobacterium longum promotes postoperative liver function recovery in patients with hepatocellular carcinoma","volume":"32","author":"Yu","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B74","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2519706","article-title":"Gut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration","volume":"17","author":"Zhang","year":"2025","journal-title":"Gut Microbes"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.cmet.2025.09.001","article-title":"Catenibacteriummitsuokai promotes hepatocellular carcinogenesis by binding to hepatocytes and generating quinolinic acid","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ph17091142","article-title":"Bile acids and liver cancer: Molecular mechanism and therapeutic prospects","volume":"17","author":"Zhang","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.524205","article-title":"The potential gut microbiota-mediated treatment options for liver cancer","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13030329","article-title":"Roles of traditional and next-generation probiotics on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A systematic review and network meta-analysis","volume":"13","author":"Zhu","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/frmbi.2025.1688681","article-title":"Impact of DNA extraction techniques and sequencing approaches on microbial community profiling accuracy","volume":"4","author":"Zoruk","year":"2025","journal-title":"Front. Microbiomes"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1852380\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:42:51Z","timestamp":1780983771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1852380\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":80,"alternative-id":["10.3389\/fcimb.2026.1852380"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1852380","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1852380"}}